Related content

Weight Gain in Women with Breast Cancer Treated with Adjuvant Cyclophosphomide, Methotrexate and 5-Fluorouracil. Analysis of Resting Energy Expenditure and Body Composition

By Rio G.D.  

Breast Cancer Research and Treatment, Vol. 73, Iss. 3, 2002-06 ,pp. : 267-273

Springer Publishing Company

Access to resources Recommend Favorite

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

By Colleoni M.   Price K.   Castiglione-Gertsch M.   Goldhirsch A.   Coates A.   Lindtner J.   Collins J.   Gelber R.D.   Thurlimann B.   Rudenstam C.M.  

European Journal of Cancer, Vol. 34, Iss. 11, 1998-10 ,pp. : 1693-1700

Elsevier

Access to resources Recommend Favorite

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

By Batey M.A.   Wright J.G.   Azzabi A.   Newell D.R.   Lind M.J.   Calvert A.H.   Boddy A.V.  

European Journal of Cancer, Vol. 38, Iss. 8, 2002-05 ,pp. : 1081-1089

Elsevier

Access to resources Recommend Favorite

Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in Breast Cancer: Is it Cost-effective?

By Norum Jan  

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 33-39

Informa Healthcare

Access to resources Recommend Favorite

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’

By demicheli R.  

Breast Cancer Research and Treatment, Vol. 53, Iss. 3, 1999-02 ,pp. : 209-215

Springer Publishing Company

Access to resources Recommend Favorite